Gilead Sciencesvs.Regeneron
GILD vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 2.1× larger than Regeneron by market cap; year to date, Gilead Sciences leads (+19.6% vs +7.3%).
Side by side
| GILD | REGN | |
|---|---|---|
| Market cap | $170B | $82.2B |
| Price | $148.77 | $833.56 |
| Today | +1.4% | +0.6% |
| Return YTD | +19.6% | +7.3% |
| Return 1Y | +27.9% | +40.5% |
| P/E | — | 19.0 |
| P/S | 5.6 | 5.3 |
| P/B | 14.4 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More GILD & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →